Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.
about
Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysisPharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approachAntidepressants, anxiolytics, and hypnotics in pregnancy and lactationCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersAntidepressant use in pregnancy: a critical review focused on risks and controversiesPrenatal antidepressant exposure: clinical and preclinical findings.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Continuing medical education: SSRIs and pregnancy.Antidepressant use in pregnancy and the risk of cardiac defectsDevelopmental origins of health and disease: environmental exposures.Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisTreatment of nonpsychotic major depression during pregnancy: patient safety and challengesEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.Case 1: A newborn in distress.Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007.Use of prescription medicines in Australian women of child-bearing age.Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good.Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyPregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.Prescribing antidepressants to pregnant women: what is a family physician to do?In utero exposure to antidepressants and the use of drugs for pulmonary diseases in childrenDuloxetine and pregnancy outcomes: safety surveillance findingsThe origins of health and disease: the influence of maternal diseases and lifestyle during gestationThe risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006.Perinatal depression: treatment options and dilemmas.Is migraine a lateralization defect?Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research.Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational studyCongenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.Problems associated with long-term treatment with selective serotonin reuptake inhibitors.Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.Safety of treatment of obsessive compulsive disorder in pregnancy and puerperium.Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: a meta-analysis of cohort studies.
P2860
Q21198704-3D6AC4DE-5D3E-467F-8068-7EDE25A3BBCCQ26774013-94213FBC-F77E-4F2F-AD73-B7A42A721A93Q26795384-CF9B3139-C385-4AD0-930B-F7248A077EFEQ27009995-A0B02169-B826-41BC-8CCD-1479F96976AFQ28281407-8B3FCC80-B10B-43D2-8D35-098B9C821744Q30415540-2869DC7C-F192-43BA-9466-708E5886B58EQ33521786-7BC5607A-8A23-472E-B9CB-90E5C658A976Q33671166-7CB4FE34-DAA1-44E8-96DD-D26FCEEC0CB0Q33775616-9852A638-1E81-4C53-A279-378C93392AFCQ33822673-299C410A-CE6C-46E8-90DD-423839FFBB94Q34144128-3E5C2A69-5089-45AF-9223-42358D5AFB5AQ34237681-AF4A0DFA-FB54-479B-92AE-5545291A387AQ34714284-18CD0B30-2787-4E59-B438-BD554AE9B3C5Q34956921-EFF4F178-0100-4ECF-B0A1-D1B9DDE608B5Q35572617-6667ACDE-4C7B-450C-9F1C-FFB8CC907F86Q35608913-EB5F4092-F37E-4DDA-AD68-6A2309BAC4EEQ35640425-05A70C81-F34A-4EF2-B31B-BC744862E2ACQ35640478-64B544E5-CB5C-4B7D-A96C-FBA4A505EF08Q35794715-A62A6EDC-BA83-4D5A-AEF8-B7B310F442EBQ35862755-5C555717-09D8-49D4-AE27-D8D5FD94B2B8Q35907475-E09085A8-D477-45CB-BE3E-1EE99E864F7FQ36045075-F87E8558-F34D-4963-AB2D-B372E8376D53Q36125487-307641A5-51DF-4F08-B946-CA08988D0A8EQ36165320-DF0DF5BA-5B1E-4FFA-A345-900570DAC705Q36447517-54A8AB14-13E1-4DAB-A8AB-C282827894B0Q36609764-4C93C0B9-A4FC-4791-B2C6-A3D73EF8A94EQ36663394-0136AE23-13FE-48AD-B276-6BC1AB2327CEQ36689210-25F66D2D-EF99-4195-A2DC-1D13EEBAC55AQ36706789-E5BDDDA2-DDF4-4235-AF27-29A58B614BCEQ36729123-68B8DCB0-8C10-4723-B15B-BEBCB85540C6Q36737979-24763BE6-DAEA-42E0-89A0-595719EAB09AQ37042005-11AC6495-EBEF-4881-80FD-5D03AF7B3F5DQ37058701-89552D66-B250-492C-9C19-6E76D56827F8Q37142457-55BC70FB-7D65-4A47-816F-8499388612AAQ37148326-6824E851-15B4-4ED2-8F10-4D15BB806F73Q37219382-C95F817B-99B8-46F3-9B90-F8D14D809B1CQ37359791-B3EBA1F1-C3D4-4016-A19B-2F3526078227Q37580549-C93A19D5-4731-487A-ABB2-25F12757DA03Q37612128-CE9A5E17-FE34-40F1-99EE-636FF655AB62Q37654878-662A8088-DE0A-4B43-8BA9-5A30B29B87BA
P2860
Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Paroxetine and congenital malf ...... potential confounding factors.
@ast
Paroxetine and congenital malf ...... potential confounding factors.
@en
Paroxetine and congenital malf ...... potential confounding factors.
@nl
type
label
Paroxetine and congenital malf ...... potential confounding factors.
@ast
Paroxetine and congenital malf ...... potential confounding factors.
@en
Paroxetine and congenital malf ...... potential confounding factors.
@nl
prefLabel
Paroxetine and congenital malf ...... potential confounding factors.
@ast
Paroxetine and congenital malf ...... potential confounding factors.
@en
Paroxetine and congenital malf ...... potential confounding factors.
@nl
P2093
P1476
Paroxetine and congenital malf ...... potential confounding factors.
@en
P2093
Anick Bérard
Benjamin Bar-Oz
Gideon Koren
Lisa O'Brien
Radinka Boskovic
Thomas Einarson
P304
P356
10.1016/J.CLINTHERA.2007.05.003
P577
2007-05-01T00:00:00Z